Gaur S [6]
|
1
|
35
|
M
|
Bevacizumab, Nab-Paclitaxel
|
SD
|
Belmont [22]
|
1
|
41
|
M
|
Bevacizumab, Carboplatin, Paclitaxel
|
PR
|
Kim [15]
|
1
|
44
|
F
|
Bevacizumab, Carboplatin, Paclitaxel
|
PD
|
Lopes [16]
|
1
|
51
|
M
|
Bevacizumab, Carboplatin, Etoposide
|
PD
|
Mizota [23]
|
1
|
59
|
F
|
Bevacizumab, Carboplatin, Paclitaxel
|
PD
|
Ye [9]
|
1
|
44
|
F
|
Bevacizumab, Carboplatin, Paclitaxel
|
SD
|
Lazarus [24]
|
1
|
42
|
M
|
Bevacizumab, Paclitaxel
|
PD
|
1
|
42
|
M
|
Carboplatin, Etoposide
|
PD
|
Salech [25]
|
1
|
40
|
F
|
Thalidomide
|
PR
|
Raphael et al. [26]
|
1
|
53
|
F
|
Thalidomide
|
SD
|
Kassam et al. [27]
|
1
|
13
|
F
|
Thalidomide
|
PD
|
Bolke et al. [28]
|
1
|
47
|
M
|
Thalidomide
|
PD
|
Mascarenhas et al. [29]
|
1
|
52
|
M
|
Thalidomide
|
PR
|
Pallotti et al. [31]
|
1
|
73
|
M
|
Lenalidomide
|
SD
|
Sumrall et al. [30]
|
1
|
31
|
F
|
Lenalidomide
|
SD
|
Agulnik et al. [18]
|
2
|
NA
|
NA
|
Bevacizumab
|
PR
|
1
|
NA
|
NA
|
Bevacizumab
|
PD
|
4
|
NA
|
NA
|
Bevacizumab
|
SD
|
Chevreau et al. [19]
|
5
|
NA
|
NA
|
Sorafenib
|
SD
|
2
|
NA
|
NA
|
Sorafenib
|
PR
|
8
|
NA
|
NA
|
Sorafenib
|
PD
|